title: A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cystic fibrosis transmembrane regulator delta F508 mutation.
abstract: Cystic fibrosis is an autosomal recessive disorder affecting chloride transport in pancreas, lung, and other tissues, which is caused by mutations in the cystic fibrosis transmembrane regulator (CFTR). The A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (CPX) stimulates 36Cl- efflux from pancreatic CFPAC-1 cells which bear the delta F508 genotype common to most cases of cystic fibrosis [Eidelman et al. (1992) Proc. Natl. Acad. Sci. U.S.A. 89, 5562-5566]. By contrast, correction of the cystic fibrosis defect by retrovirus-mediated gene transfer renders the resulting CFPAC-PLJ-CFTR cells insensitive to CPX. We now report that CPX also activates chloride efflux from the CF tracheal epithelial cell line IB3-1 bearing a delta F508 allele, but not if the IB3-1 cells have been repaired by transfection of the wild-type CFTR gene. Similar results were obtained with recombinant NIH 3T3 cells, in which CPX activates 36Cl- efflux from cells expressing the CFTR (delta F508) gene product but not from 3T3 cells expressing the wild-type CFTR. In all three cell types expressing CFTR (delta F508), CPX was found to activate 36Cl- efflux in a dose-dependent manner over the concentration range of 1-30 nM and then gradually lose potency at higher CPX concentrations. Six CPX analogues, A1 receptor antagonists of affinity similar to that of CPX, were found to be much less effective than CPX at activating 36Cl- efflux from CFPAC-1 cells. These included 2-thio-CPX. CPT (8-cyclopentyl-1,3-dimethylxanthine),3,4-dehydro-CPX,3-F-CPX,3-1-CPX, and KW-3902 (8-noradamantyl-1,3-dipropylxanthine).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Laboratory of Cell Biology and Genetics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: C
authors.initials: C
authors.lastname: Guay-Broder
authors.forename: K A
authors.initials: KA
authors.lastname: Jacobson
authors.forename: S
authors.initials: S
authors.lastname: Barnoy
authors.forename: Z I
authors.initials: ZI
authors.lastname: Cabantchik
authors.forename: W B
authors.initials: WB
authors.lastname: Guggino
authors.forename: P L
authors.initials: PL
authors.lastname: Zeitlin
authors.forename: R J
authors.initials: RJ
authors.lastname: Turner
authors.forename: L
authors.initials: L
authors.lastname: Vergara
authors.forename: O
authors.initials: O
authors.lastname: Eidelman
authors.forename: H B
authors.initials: HB
authors.lastname: Pollard
mesh_terms: D000818:Animals; D002460:Cell Line; D002712:Chlorides / Q000378:metabolism*; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D006801:Humans; D017136:Ion Transport / Q000187:drug effects; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D009154:Mutation; D011188:Potassium / Q000378:metabolism; D058915:Purinergic P1 Receptor Antagonists; D014970:Xanthines / Q000494:pharmacology*
chemical_list: C505032:CFTR protein, human; D002712:Chlorides; D008565:Membrane Proteins; D058915:Purinergic P1 Receptor Antagonists; D014970:Xanthines; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; C051360:1,3-dipropyl-8-cyclopentylxanthine; D011188:Potassium